ONL-1204 is under clinical development by ONL Therapeutics and currently in Phase I for Open-Angle Glaucoma. According to GlobalData, Phase I drugs for Open-Angle Glaucoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ONL-1204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONL-1204 is under development for the treatment of retinal detachment, retinitis pigmentosa, non-infectious uveitis, open angle glaucoma, geographic atrophy, chronic glaucoma, dry and wet age-related macular degeneration. The drug candidate is administered through intravitreal route. It is a small molecule peptide analog of Met12 that acts by targeting the Fas receptor. It was also under development for
ONL Therapeutics overview
ONL Therapeutics is a biopharmaceutical company which is focused on protecting and improving the vision of patients with a range of retinal disease and conditions.? ONL Therapeutics is headquartered in Ann Arbor, Michigan, the US.
For a complete picture of ONL-1204’s drug-specific PTSR and LoA scores, buy the report here.